ReviewFrontiers in oncology2021
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy.
Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 71 citations in OpenAlex.
- Immunohistochemical Predictors in Head and Neck Mucosal Melanoma.Head and neck pathology · 2026Article
- Generation of an NG2 targeting bispecific antibody for the induction of T-cell immunity against melanoma.Journal of translational medicine · 2026Article
- Mucosal melanoma in 1481 patients in the Netherlands. An overview of metastatic patterns, main driver mutations and the efficacy of therapeutic strategies.BJC reports · 2026Article
- Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.Pigment cell & melanoma research · 2026Review
- Genomic profiling and therapeutic targets of Thai melanoma revealed by next-generation sequencing.Scientific reports · 2026Article
- Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma.Science advances · 2026Article
- Primary Malignant Melanoma of the Nasolacrimal Duct Presenting Without Hemolacria: A Case Report and Literature Review.Current oncology (Toronto, Ont.) · 2026Article
- Multimodality Imaging in Cardiac Metastasis of Cutaneous Melanoma: Case Report and Systematic Review.Journal of cardiovascular development and disease · 2026Article
- Vulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?Frontiers in oncology · 2026Review
- From Malaise to Oral Pain: A Case Report on Oral Mucosal Melanoma.Case reports in dentistry · 2026Article
- Transanal sphincter-sparing local excision for primary anorectal malignant melanoma: a case report.Frontiers in oncology · 2026Article
- Expression of Glutamatergic Signaling in Canine Oral Melanocytic Neoplasms.Veterinary sciences · 2025Article
- Sinonasal Mucosal Melanoma Survival Outcomes, Recurrence Patterns, and Prognostic Factors: A Systematic Literature Review and Meta-analysis of Publications after 2000.Journal of neurological surgery. Part B, Skull base · 2025Article
- Review
- Multifocal Oral Mucosal Melanoma with an Atypical Clinical Presentation.Dentistry journal · 2025Article
- The Roles of PTEN in Melanoma Suppression.Pigment cell & melanoma research · 2025Review
- Article
- Capacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma.Cancers · 2025Article
- Combination Immunotherapy for Mucosal Melanoma: Molecular Mechanism, Research Status, and Future Directions.Current treatment options in oncology · 2025Review
- Capacity for compensatory cyclin D2 response confers trametinib resistance in canine mucosal melanoma.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal melanoma (MM) is a rare melanoma subtype that originates from melanocytes within sun-protected mucous membranes. Compared with cutaneous melanoma (CM), MM has worse prognosis and lacks effective treatment options. Moreover, the endogenous or exogenous risk factors that influence mucosal melanocyte transformation, as well as the identity of MM precursor lesions, are ambiguous. Consequently, there remains a lack of molecular markers that can be used for early diagnosis, and therefore better management, of MM. In this review, we first summarize the main functions of mucosal melanocytes. Then, using oral mucosal melanoma (OMM) as a model, we discuss the distinct pathologic stages from benign mucosal melanocytes to metastatic MM, mapping the possible evolutionary trajectories that correspond to MM initiation and progression. We highlight key areas of ambiguity during the genetic evolution of MM from its benign lesions, and the resolution of which could aid in the discovery of new biomarkers for MM detection and diagnosis. We outline the key pathways that are altered in MM, including the MAPK pathway, the PI3K/AKT pathway, cell cycle regulation, telomere maintenance, and the RNA maturation process, and discuss targeted therapy strategies for MM currently in use or under investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.